FDA Panel Can't Decide Whether Agency Should Issue Nanotechnology Guidance
This article was originally published in The Gold Sheet
Executive Summary
Do nanotechnology-derived drugs merit their own GMPs? That remains an open question, say FDA advisors, unsure whether nanoguidance is warranted.